Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis

Journal of Clinical Gastroenterology

Volumn 45, Issue 2, 2011, Pages 149-152

  Verdam, Froukje J ^a   Rensen, Sander S ^a   Driessen, Ann ^b   Greve, Jan Willem ^a   Buurman, Willem A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies to endotoxin; EndoCab; leaky gut; nonalcoholic fatty liver disease

Indexed keywords

ENDOTOXIN; IMMUNOGLOBULIN G;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIVER BIOPSY; LONG TERM EXPOSURE; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL;

ADULT; ANTIBODIES; ENDOTOXINS; FATTY LIVER; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIVER; MALE; MIDDLE AGED; OBESITY;

EID: 78951470255     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181e12c24     Document Type: Article

References (21)

1. Duvnjak M, Lerotic I, Barsic N, et al. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 2007;13:4539-4550.
2. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877-1887.
3. Sabate JM, Jouet P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg. 2008;18: 371-377.
4. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48: 206-211.
5. Farhadi A, Gundlapalli S, Shaikh M, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in nonalcoholicsteatohepatitis. Liver Int. 2008;28:1026-1033.
6. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008;138:1452-1455.
7. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 1988;8:232-236.
8. Cohen J, McConnell JS. Observations on the measurement and evaluation of endotoxemia by a quantitative limulus lysate microassay. J Infect Dis. 1984;150:916-924.
9. Ditter B, Becker KP, Urbaschek R, et al. Quantitative endotoxin determination. Automated kinetic Limulus amebocyte lysate microtiter test with measurement of sample-related interferences. Arzneimittelforschung. 1983;33:681-687.
10. Cohen O, Reichenberg A, Perry C, et al. Endotoxin-induced changes in human working and declarative memory associate with cleavage of plasma readthrough acetylcholinesterase. J Mol Neurosci. 2003;21:199-212.
11. Hurley JC. Endotoxemia: methods of detection and clinical correlates. Clin Microbiol Rev. 1995;8:268-292.
12. Cohen J. The detection and interpretation of endotoxaemia. Intensive Care Med. 2000;26(suppl 1):S51-S56.
13. Shiomi S, Kuroki T, Ueda T, et al. Use of immobilized histidine in assay for endotoxin in patients with liver disease. J Gastroenterol. 1994;29:751-755.
14. Nakao A, Yasui M, Kawagoe T, et al. False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology. 1997;44:1413-1418.
15. Barclay GR, Scott BB, Wright IH, et al. Changes in antiendotoxin- IgG antibody and endotoxaemia in three cases of gram-negative septic shock. Circ Shock. 1989;29:93-106.
16. Scott BB, Barclay GR. Endotoxin-polymyxin complexes in an improved enzyme-linked immunosorbent assay for IgG antibodies in blood donor sera to gram-negative endotoxin core glycolipids. Vox Sang. 1987;52:272-280.
17. Clements WD, Erwin P, McCaigue MD, et al. Conclusive evidence of endotoxaemia in biliary obstruction. Gut. 1998;42: 293-299.
18. Gardiner KR, Halliday MI, Barclay GR, et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut. 1995;36:897-901.
19. Rensen SS, Slaats Y, Driessen A, et al. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology. 2009;50:1809-1817.
20. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474.
21. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.